Variants in the CYP2B6 3′UTR Alter In Vitro and In Vivo CYP2B6 Activity: Potential Role of MicroRNAs-Reference-Cited by-同舟云学术

Variants in the CYP2B6 3′UTR Alter In Vitro and In Vivo CYP2B6 Activity: Potential Role of MicroRNAs

Published:2017-10-25 Issue:1 Volume:104 Page:130-138
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Burgess Kimberly S.¹²,Ipe Joseph²,Swart Marelize²,Metzger Ingrid F.²,Lu Jessica²,Gufford Brandon T.²,Thong Nancy²,Desta Zeruesenay²,Gaedigk Roger³,Pearce Robin E.³,Gaedigk Andrea³,Liu Yunlong⁴⁵,Skaar Todd C.²

Affiliation:

1. Department of Pharmacology & Toxicology; Indiana University School of Medicine; Indianapolis Indiana USA

2. Department of Medicine, Division of Clinical Pharmacology; Indiana University School of Medicine; Indianapolis Indiana USA

3. Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Kansas City; Kansas City Missouri USA

4. Department of Medical & Molecular Genetics; Indiana University School of Medicine; Indianapolis Indiana USA

5. Center for Computational Biology and Bioinformatics; Indiana University School of Medicine; Indianapolis Indiana USA

Funder

NIH/NIGMS

Clinical Pharmacology Training

Vera Bradley Foundation for Breast Cancer

The National Institute of Child Health and Human Development Brain and Tissue Bank for Developmental Disorders at the University of Maryland

National Institutes of Health

Liver Tissue Cell Distribution System

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference34 articles.

1. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro;Desta;Pharmacogenomics,2007

2. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz;Klein;Pharmacogenet. Genomics,2005

3. Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver;Hofmann;J. Pharmacol. Exp. Ther.,2008

4. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers;Eap;Clin. Pharmacol. Ther.,2007

5. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients;Nakajima;Pharmacogenet. Genomics,2007

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of genetic variations of 3′-UTR in clopidogrel pharmacokinetic-relevant genes with clopidogrel response in Han Chinese patients with coronary artery disease;European Journal of Pharmaceutical Sciences;2024-09

2. Novel Approaches to Characterize Individual Drug Metabolism and Advance Precision Medicine;Drug Metabolism and Disposition;2023-07-07

3. SNPs in 3′UTR miRNA Target Sequences Associated with Individual Drug Susceptibility;International Journal of Molecular Sciences;2022-11-08

4. Influence of CYP2B6 Pharmacogenetics on Stereoselective Inhibition and Induction of Bupropion Metabolism by Efavirenz in Healthy Volunteers;Journal of Pharmacology and Experimental Therapeutics;2022-07-07

5. A single nucleotide polymorphism-based formula to predict the risk of propofol TCI concentration being over 4 µg mL−1 at the time of loss of consciousness;The Pharmacogenomics Journal;2022-01-22